The survival and sequestration of transfused donor platelets in cytostatic cytopenias


Cite item

Full Text

Abstract

Aim. To study the survival and sequestration of transfused donor platelets labeled with 51Cr in patients with acute leukemia (AL).
Subjects and methods. Seven donor volunteers and 39 patients with different forms with AL at various stages of polychemotherapy (PCT) were examined. Cytostatic therapy was accompanied by 51Cr-labeled platelet concentrate (PC) transfusions. The patients were on appropriate high-dose (HD) PCT.
Results. The duration of donor platelet circulation was 8-10 days in healthy individuals. No platelet hypersequestration was recorded in both the spleen and the liver. Donor platelet survival was shorter in all patients with in a state of cytostatic cytopenia. There was an inverse correlation between the degree of circulation shortening and some clinical and hematological parameters (the bone marrow level of blastemia and blastosis, the XIIa-dependent fibrinolysis parameters). Four variants of radioactivity trends above the spleen and liver were identified. The findings suggest that there is platelet hypersequestration in the spleen, liver, and both organs. In some patients, the above both organs are uninvolved in the hypersequestration processes and the possible mechanism for increased consumption of transfused donor platelets, which is associated with recovery of the HD PCT-damaged vascular endothelium is considered.
Conclusion. Shortening of transfused donor platelet circulation was found in relation to the level of blastosis. The described procedure may be used as one of the additional methods for evaluating the efficacy of donor PC transfusion and for specifying the pathogenesis of thrombocytopenias in AL patients on programmed HD PCT. A procedure is proposed to time the circulation of 51Cr-labeled platelets, by assessing deposit phenomena and estimating the level of their sequestration in the spleen and liver for the prediction of the efficiency of TC transfusions.

About the authors

Ekaterina Valentinovna Migunova

Email: nuclear@blood.ru

Yashin Daminovich Sakhibov

Email: nuclear@blood.ru

Vyacheslav Vladimirovich Ryzhko

Ol'ga Markovna Sorkina

Nadzhiya Shavkatovna Sagdieva

Email: gamma@blood.ru

Eduard Georgievich Gemdzhyan

Email: ed366@mail.ru

E V Migunova

Hematology Research Center, Russian Academy of Medical Sciences

Hematology Research Center, Russian Academy of Medical Sciences

Ya D Sakhibov

Hematology Research Center, Russian Academy of Medical Sciences

Hematology Research Center, Russian Academy of Medical Sciences

V V Ryzhko

Hematology Research Center, Russian Academy of Medical Sciences

Hematology Research Center, Russian Academy of Medical Sciences

O M Sorkina

Hematology Research Center, Russian Academy of Medical Sciences

Hematology Research Center, Russian Academy of Medical Sciences

N Sh Sagdiyeva

Hematology Research Center, Russian Academy of Medical Sciences

Hematology Research Center, Russian Academy of Medical Sciences

E G Gemdzhyan

Hematology Research Center, Russian Academy of Medical Sciences

Hematology Research Center, Russian Academy of Medical Sciences

References

  1. Воробьев А. И., Бриллиант М. Д., Савченко В. Г. Руководство по гематологии. М.; 2002; т. 1: 201-204.
  2. Савченко В. Г., Паровичникова Е. Н. Лечение острых лейкозов (Клинические исследования). М.: МЕДпресс-информ; 2004. 224-232.
  3. Сведенцов Е. П. Переливание концентрата тромбоцитов. В кн.: Руководство по трансфузионной медицине. Киров; 1999. 412-418.
  4. Сахибов Я. Д. Клиническая эффективность и приживляемость донорских тромбоцитов. В кн.: Сведенцов Е. П. и др. Заготовка и консервирование тромбоцитов для клинического применения. Ташкент: 1996. 76-85.
  5. Сахибов Я. Д., Сагдиева Н. Ш., Новокщенова Л. В. К вопросу о выживаемости тромбоцитов при некоторых заболеваниях крови. Тер. арх. 1992; 12: 48-51.
  6. Мигунова Е. В., Сахибов Я. Д., Сагдиева Н. Ш. и др. Радионуклидное 51Cr определение выживаемости и секвестрации облученных донорских тромбоцитов у больных острыми лейкозами. Мед. радиол. 2009; 1, 54(2): 69-72.
  7. Snyder E. L., Baril L., Corda T. Protocol for 51Cr and 111In radiolabeling of frech blood platelets in vitro. Transfusion 2004; 44: 76A.
  8. Tsukada T., Tango T. On the methods calculating mean survival time in 51Cr-platelet survival study. Am. J. Hematol. 1980; 8: 281.
  9. Holme S., Heaton A., Roodt J. Concurrent label method with 111In- and 61Cr allows accurate evaluation of platelet viability of stored platelet concentrates. Br. J. Haematol. 1993; 84: 717- 723.
  10. Dumontm L. J. Analysis and reporting of platelet kinetic stadies. Transfusion 2006; 46S: 67-73.
  11. De Vos F. U., Willemse P. H.., De Vries E. G. Endothelial cell effects of cytotoxics: balans between desired and unwanted effects. Cancer Treat. Rev. 2004; 30: 495-513.
  12. Doll D. C., Yarbro J. W. Vascular toxicity associated with chemotherapy agents. Semin. Oncol. 1992; 19(5): 580-596.
  13. Баркаган З. С. Нарушения гемостаза при онкогематологических заболеваниях. В кн.: Воробьев А. И. Руководство по гематологии. М.; 2005; т. 3: 129-130.

Copyright (c) 2010 Migunova E.V., Sakhibov Y.D., Ryzhko V.V., Sorkina O.M., Sagdieva N.S., Gemdzhyan E.G., Migunova E.V., Sakhibov Y.D., Ryzhko V.V., Sorkina O.M., Sagdiyeva N.S., Gemdzhyan E.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies